摘要
背景与目的:16α-18F-17β-雌二醇(18F-FES)作为雌激素受体(estrogen receptor,ER)特异性显像剂,可在活体内反映ER的表达状况。本研究主要探讨乳腺癌患者体内18F-FES摄取结果与病理免疫组化的相关性。方法:自行制备18F-FES,入组26例乳腺癌患者(17例原发性乳腺癌,9例复发转移性乳腺癌),分别进行18F-FES及18F-FDG PET/CT显像,对每例患者进行空心针穿刺或手术治疗,对比相应病灶的免疫组化和18F-FES、18F-FDG摄取结果。结果:96.15%(25/26)的患者18F-FES结果与ER病理免疫组化一致,以18F-FES SUVmax≥1.5为ER阳性,18F-FES PET/CT显像诊断乳腺癌病灶ER阳性的灵敏度为93.33%,特异度为100%。ER、PR的免疫组化结果与18F-FES的SUVmax呈明显的正相关;HER-2/Neu的免疫组化结果与18F-FES的SUVmax呈负相关。结论:18F-FES有望用于全面反映乳腺癌患者全身病灶的ER表达情况,为临床个体化治疗方案的制定提供帮助。
Background and purpose： 16α-[^18F]fluoroestradiol （^18F-FES） is an in vivo specific imaging agent for estrogen receptor （ER）. We investigated the concordance between tumor ER status as determined by FES-PET and in vitro immunobistochemical assays. Methods： ^18F-FES was prepared by ourselves. Twenty-six patients were enrolled （17 primary and 9 metastatic/recurrent）. Patients underwent both ^18F-FES and ^18F-FDG PET/CT. Results： We found good overall agreement （96.15%） between in vitro ER assays and FES-PET. The ER status diagnosis sensitivity of ^18F-FES was 93.33% and the specificity was 100% when using cut-off value of SUVmax≥ 1.5. There was a positive correlation between in vitro ER, PR assays and the SUVmax of ~SF-FES while in vitro HER-2/neu assays correlatived negatively with 18F-FES SUVmax. Conclusion： These results suggested ^18F-FES may be useful for studying the ER expression of all malignant lesions in natients with breast cancer and guiding individual therapy.
出处
《中国癌症杂志》
CAS
CSCD
北大核心
2014年第2期128-134,共7页
China Oncology
